AbbVie announced that FDA and EMA have granted orphan drug status to its investigational anti-epidermal growth factor receptor antibody drug conjugat, ABT-414, for the treatment of glioblastoma multiforme.
AbbVie announced that FDA and EMA have granted orphan drug status to its investigational anti-epidermal growth factor receptor antibody drug conjugate, ABT-414, for the treatment of glioblastoma multiforme.
It is estimated that each year in the US and Europe, two to three of every 100,000 people are diagnosed with the glioblastoma multiforme. The disease is the most common and aggressive form of malignant primary brain tumor with a 4% survival rate of five years.
"The orphan drug designation is an important regulatory advancement as we further our development in recurrent glioblastoma multiforme, a disease that is uniformly fatal with limited treatment options," said Gary Gordon, MD, vice president, oncology clinical development, AbbVie, in a press statement. "We are pleased to continue developing ABT-414 in Phase II trials in patients with glioblastoma multiforme based on the results of our Phase I program."
Results from the Phase I studies evaluating ABT-414 in patients with recurrent or unresectable glioblastoma multiforme were presented at the 50th American Society of Clinical Oncology (ASCO) meeting in Chicago earlier this year.
Source: AbbVie
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.